|By Marketwired .||
|August 6, 2014 08:05 AM EDT||
CEDAR KNOLLS, NJ -- (Marketwired) -- 08/06/14 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has published a white paper entitled "The Impact of Fortetropin on Muscle." The white paper provides additional results of its clinical trial designed to study the effects of Fortetropin in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa.
As discussed in the white paper, the University of Tampa clinical trial was a double-blind, placebo-controlled trial which examined the effects of Fortetropin on skeletal muscle growth, lean body mass, strength, and power in recreationally trained individuals who rely heavily on satellite cell activation. Forty-five subjects were divided into placebo, 6.6g and 19.8g dosing arms of Fortetropin daily for a period of 12 weeks. Results demonstrated a statistically significant increase in both muscle thickness and lean body mass in subjects taking Fortetropin compared to placebo. Strength and power endpoints, as measured by bench press, leg press and Wingate power, significantly increased from baseline in all study groups. Additionally, a statistically significant decrease in fat mass in subjects in the 19.8 g arm was noted.
Currently MYOS' bionutritional supplement Fortetropin is the only safe and naturally occurring myostatin inhibitor available with clinically demonstrated positive effect on both muscle thickness and lean body mass compared to placebo.
The white paper explains the role of myostatin, a transforming growth factor-beta (TGF-β) superfamily protein, which is a key regulator of muscle health and regeneration. Studies have shown that the reduction or inhibition of myostatin has an effect on muscle growth and is an important target in drug development efforts focused on the preservation of muscle tissue. In the medical community it is well known that maintaining muscle mass and muscle quality is an important key marker for overall health and is central to the management of aging and many chronic illnesses.
More information on the impact of Fortetropin on muscle and overall health can be found in the MYOS white paper "The Impact of Fortetropin on Muscle," which is available on the Company's website at www.myoscorp.com. Please click here to access the white paper directly.
About MYOS Corporation
MYOS is a developmental stage biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin (MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company," visit www.myoscorp.com.
The Company's first commercial product based on Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin (MYO-T12®) and its effects on myostatin inhibition, including our research and development activities, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products including the proposed products described herein, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
MYOS Corporation Investor and Media Contact:
Investor Relations and Corporate Communications
Jul. 24, 2016 02:45 AM EDT Reads: 837
Jul. 24, 2016 02:00 AM EDT Reads: 1,809
Jul. 24, 2016 01:30 AM EDT Reads: 1,105
Jul. 24, 2016 01:15 AM EDT Reads: 1,206
Jul. 24, 2016 01:15 AM EDT Reads: 828
Jul. 24, 2016 12:30 AM EDT Reads: 1,548
Jul. 23, 2016 11:45 PM EDT Reads: 1,199
Jul. 23, 2016 11:30 PM EDT Reads: 2,101
Jul. 23, 2016 11:30 PM EDT Reads: 816
Jul. 23, 2016 11:15 PM EDT Reads: 1,852
Jul. 23, 2016 11:15 PM EDT Reads: 1,220
Jul. 23, 2016 11:00 PM EDT Reads: 2,221
Jul. 23, 2016 10:15 PM EDT Reads: 2,429
Jul. 23, 2016 10:00 PM EDT Reads: 1,574
Jul. 23, 2016 10:00 PM EDT Reads: 1,583